Compare STRS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRS | EDIT |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.3M | 206.0M |
| IPO Year | N/A | 2016 |
| Metric | STRS | EDIT |
|---|---|---|
| Price | $29.97 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 11.5K | ★ 1.8M |
| Earning Date | 11-12-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,912,000.00 | ★ $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.10 | $0.91 |
| 52 Week High | $31.35 | $4.54 |
| Indicator | STRS | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 65.14 | 31.81 |
| Support Level | $28.85 | $1.92 |
| Resistance Level | $31.35 | $2.11 |
| Average True Range (ATR) | 0.96 | 0.16 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 69.60 | 0.03 |
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations. Real Estate Operations segment encompasses activities associated with entitlement, development, and sale of real estate. Leasing Operations segment involves leasing of commercial space at retail and mixed-use properties and residences in multi-family properties that company developed. Majority of revenue is from Real Estate Operations.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.